Arcus Biosciences: High Stakes for 2026 With Key Cancer Drug Readouts

HAYWARD, CA – February 11, 2026 – Arcus Biosciences (NYSE:RCUS) is poised for a pivotal year, and all eyes will be on its management team later this month. The clinical-stage biopharmaceutical company announced it will host a conference call on February 25th to discuss its fourth-quarter and full-year 2025 financial results. While the numbers will provide a crucial snapshot of the company's fiscal health, investors and analysts will be listening most intently for updates on a clinical pipeline brimming with potential blockbuster therapies, particularly its late-stage cancer drugs casdatifan and quemliclustat.

The upcoming call serves as a critical checkpoint for a company that has seen its market valuation soar over the past year, driven by promising clinical data and strategic partnerships. With multiple data readouts on the horizon in 2026, the discussion will set the tone for a period that could define the company's trajectory from a clinical-stage developer to a commercial powerhouse.

A Financial Fortress for High-Stakes R&D

For any clinical-stage biotech, the balance between cash burn and clinical progress is paramount. Arcus appears to be navigating this challenge from a position of strength. As of its last report at the end of the third quarter of 2025, the company held a robust $841 million in cash and investments. This substantial war chest is projected to fund operations through the second half of 2028, providing a crucial runway to see its most advanced programs through initial pivotal readouts.

This financial stability is underpinned by significant backing from its major partner, Gilead Sciences, which increased its ownership stake to 33% with a $320 million equity investment in early 2024. While Arcus reported lower collaboration revenue in Q3 2025 compared to the prior year, its full-year 2025 GAAP revenue guidance was projected to be between $225 million and $235 million.

Analysts are watching the company’s spending closely. Research and Development (R&D) expenses rose to $141 million in Q3 2025, fueled by the costs of advancing its late-stage trials. However, Arcus has guided that it expects R&D expenses to begin declining, partly due to the winding down of costs associated with its domvanalimab Phase 3 development program. For the upcoming fourth-quarter results, analyst consensus places the estimated earnings per share (EPS) at -$1.03, reflecting the continued heavy investment required to bring novel therapies to market.

Casdatifan Takes Aim at Kidney Cancer Market

The centerpiece of investor excitement is casdatifan, an investigational HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. Arcus is positioning its drug as a potential best-in-class therapy, directly challenging Merck & Co.'s approved HIF-2α inhibitor, Welireg (belzutifan). The company's confidence is backed by compelling data from its Phase 1/1b ARC-20 study.

A pooled analysis of 121 late-line kidney cancer patients showed casdatifan achieved a median progression-free survival (mPFS) of 12.2 months and an impressive objective response rate (ORR) of 34.4%. These metrics have fueled the narrative that casdatifan could offer superior durability and response compared to existing options. Investors are anticipating an imminent update, with more mature data from the study’s monotherapy cohorts expected at a medical conference this month.

Further catalysts are expected throughout 2026. Arcus is actively enrolling patients in its global Phase 3 PEAK-1 study, which evaluates casdatifan in combination with cabozantinib for patients whose cancer has progressed after immunotherapy. Additionally, more data from combination cohorts within the ARC-20 study are expected by mid-2026. These readouts will be critical in validating the drug's potential and shaping its competitive profile in a rapidly evolving treatment landscape.

Diversifying the Attack on Cancer and Beyond

Beyond its lead candidate, Arcus is advancing a broad and strategically diversified portfolio. Another key late-stage asset, quemliclustat, a small-molecule CD73 inhibitor, is being evaluated for pancreatic cancer—one of the most difficult-to-treat solid tumors. The Phase 3 PRISM-1 trial, which combines quemliclustat with standard-of-care chemotherapy, was initiated in late 2024 and is a long-term value driver, with primary results expected in the first half of 2027. The company’s partner, Taiho Pharmaceutical, is running the study in Japan, highlighting the global effort behind the program.

Arcus has also demonstrated a nimble approach to portfolio management. While its anti-TIGIT antibody, domvanalimab, showed promising overall survival data in a gastric cancer study, the company is strategically winding down certain trials to focus resources. A key analysis of the STAR-121 Phase 3 study, evaluating domvanalimab in first-line non-small cell lung cancer in collaboration with Gilead, is anticipated in the first quarter of 2026 and remains a significant event.

Looking to the future, Arcus has signaled its ambition to expand beyond oncology. In 2025, it unveiled a new portfolio of five programs targeting inflammatory and autoimmune diseases. The first of these, a molecule for chronic spontaneous urticaria, is slated to enter the clinic in 2026, followed by an oral TNF inhibitor for conditions like rheumatoid arthritis and psoriasis in late 2026 or early 2027. This expansion represents a deliberate strategy to leverage its discovery engine to address a wider range of unmet medical needs.

Strategic Alliances and Surging Market Confidence

The company's progress has not gone unnoticed by the market. Arcus Biosciences' stock (RCUS) has been on a remarkable run, with its market capitalization increasing by over 114% in the last year to approximately $2.61 billion. The stock recently touched a 52-week high, reflecting strong investor belief in the pipeline's potential.

Analyst sentiment is largely positive, with a "Moderate Buy" consensus rating and an average 12-month price target of $30.00. Goldman Sachs recently upgraded the stock to a "Buy," citing a potential $1.7 billion in peak sales for casdatifan alone. This optimism is balanced by a more cautious outlook from firms like Morgan Stanley, which noted a balanced risk/reward profile.

This momentum is built not only on promising science but also on a foundation of powerful strategic collaborations. The deep-seated partnership with Gilead provides financial muscle and co-development expertise. Meanwhile, alliances with Exelixis and AstraZeneca for combination studies involving casdatifan further validate the asset and expand its potential applications across different treatment settings. As Arcus prepares to share its latest updates, the interplay between its financial discipline, clinical execution, and strategic partnerships will be front and center, defining the narrative for this increasingly prominent player in the biopharmaceutical landscape.